Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (201-210 of 206) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 206 results.
Blood|December 21, 2012
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infectionCormac Cosgrove, James E Ussher, Andri Rauch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 30, 2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005Bruno Hoen, David A Cooper, Fiona C Lampe, et al.
The Journal of Infectious Diseases|January 13, 2017
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJulien Nyombayire, Omu Anzala, Brian Gazzard, et al.
Lancet (London, England)|September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialSheena McCormack, David T Dunn, Monica Desai, et al.
HIV Medicine|August 20, 2011
British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011Mark Nelson, David Dockrell, Simon Edwards, et al.
Plos One|August 14, 2019
Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015Dorthe Raben, Ann Kathleen Sullivan, Amanda Mocroft, et al.
Pageof 21

Showing results (201-210 of 206) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 206 results.
Blood|December 21, 2012
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infectionCormac Cosgrove, James E Ussher, Andri Rauch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 30, 2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005Bruno Hoen, David A Cooper, Fiona C Lampe, et al.
The Journal of Infectious Diseases|January 13, 2017
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJulien Nyombayire, Omu Anzala, Brian Gazzard, et al.
Lancet (London, England)|September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialSheena McCormack, David T Dunn, Monica Desai, et al.
HIV Medicine|August 20, 2011
British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011Mark Nelson, David Dockrell, Simon Edwards, et al.
Plos One|August 14, 2019
Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015Dorthe Raben, Ann Kathleen Sullivan, Amanda Mocroft, et al.
Pageof 21